Page 808 - Basic _ Clinical Pharmacology ( PDFDrive )
P. 808
794 SECTION VIII Chemotherapeutic Drugs
These compounds have not yet been studied in humans. Pend- of drugs. In the face of continuing development of resistance,
ing the identification and development of new targets and considerable effort will be required to maintain the effectiveness
compounds, we will have to rely on currently available families of these drug groups.
18
16
14
12
Approvals 10 8
6
4
2
0
1983–1987 1988–1992 1993–1997 1998–2002 2003–2007 2008–2012
Decline in the number of new systemic antibacterial drugs approved by the FDA over a 30-year period. (Reproduced, with permission, from Boucher
HW et al: 10 × '20 progress-development of new drugs active against Gram-negative bacilli: An update from the Infectious Diseases Society of America. Clin Infect Dis
2013;56:1685. By permission of Oxford University Press on behalf of the Infectious Diseases Society of America. Modified, with permission, from Spellberg B et al: Trends in
antimicrobial drug development: Implications for the future. Clin Infect Dis 2004;38:1279. By permission of Oxford University Press.)
